×

Before you go!

Sign up for the FREE weekly email newsletter from the publishers of American Nurse Today. You’ll get breaking news features, exclusive investigative stories, and more — delivered to your inbox.

Sign up today!

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
Drugs and Devices

FDA approves first targeted therapy for bladder cancer

On April 12, the FDA approved Balversa (erdafitinib) for adult patients with locally advanced or metastatic bladder cancer that has a susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following previous platinum-containing chemotherapy.

Read more at fda.gov.

Leave a Reply

Your email address will not be published. Required fields are marked *

 

By submitting this form, you agree to our comment policy.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing